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Disorders of sex development (DSD) are deﬁned as a congenital condition in which development of chromosomal, gonadal or
anatomical sex is atypical. DSD patients with gonadal dysgenesis or hypovirilization, containing part of the Y chromosome (GBY),
have an increased risk for malignant type II germ cell tumors (GCTs: seminomas and nonseminomas). DSD may be diagnosed in
newborns (e.g., ambiguous genitalia), or later in life, even at or after puberty. Here we describe three independent male patients
with a GCT; two were retrospectively recognized as DSD, based on the histological identiﬁcation of both carcinoma in situ and
gonadoblastoma in a single gonad as the cancer precursor. Hypospadias and cryptorchidism in their history are consistent with
this conclusion. The power of recognition of these parameters is demonstrated by the third patient, in which the precursor lesion
was diagnosed before progression to invasiveness. Early recognition based on these clinical parameters could have prevented
development of (metastatic) cancer, to be treated by systemic therapy. All three patients showed a normal male 46,XY karyotype,
withoutobviousgeneticrearrangementsbyhigh-resolutionwhole-genomecopynumberanalysis.Thesecasesdemonstrateoverlap
between DSD and the so-called testicular dysgenesis syndrome (TDS), of signiﬁcant relevance for identiﬁcation of individuals at
increased risk for development of a malignant GCT.
1.Introduction
Congenital conditions in which development of chromo-
somal, gonadal, or anatomical sex is atypical are termed
“Disorders of Sex Development” (DSD) [1] and have re-
placed the formerly used “intersex” term. It is estimated that
DSD aﬀects 1 in 4,500 to 5,000 live births in the general
population, although with variability regarding the various
DSDsubtypes[1].DSDpatientsaresubdividedintodiﬀerent
entities:46,XYDSD,46,XXDSD,andsexchromosomalDSD.
Within these subgroups, patients, with gonadal dysgenesis
(GD) and hypovirilization with presence of part of the Y
chromosome(i.e.,GBY),areknowntohaveanincreasedrisk
to develop carcinoma in situ (CIS) or gonadoblastoma (GB),
the precursor lesions of seminoma(SE)/dysgerminoma(DG)
and nonseminoma, referred to as malignant type II germ
cell tumors (GCTs) ([2–4], for review). In GD migration
of the germ cells and/or their organization in the gonads is
disturbed, leading to incomplete formation of the gonads.
Hypovirilization is caused by defects in androgen-dependent
target tissues, errors in testosterone biosynthesis, and tes-
ticular unresponsiveness to stimulation from the pituitary2 International Journal of Endocrinology
[5], leading to underdevelopment of the male diﬀerentiation
lineage.
GB is the in situ germ cell malignancy of the ovary and
dysgenetic gonad which, in a signiﬁcant number of cases,
will develop into an invasive dysgerminoma or, less often,
nondysgerminoma, being histologically and genetically
counterparts of testicular seminoma and nonseminoma [6].
GB is composed of a mixture of embryonic germ cells
(OCT3/4 and SCF (oﬃcial term: KITLG) positive, amongst
others)andsupportivecells,withcharacteristicsofgranulosa
cells (FOXL2 positive) [7]. GB can be found in undiﬀeren-
tiated gonadal tissue and in gonadal tissue with immature
testis diﬀerentiation [8], overall related to a low level of
testicularization(i.e.,leveloftestisformation).CIS(cellsalso
positive for OCT3/4 and SCF, amongst others), on the other
hand, being the precursor of the similar types of cancer (SE
and nonseminoma) of the testis, is associated with SOX9-
positive Sertoli cells [7] and is found in well-diﬀerentiated
testicular tissue [9].
For malignant transformation of embryonic germ cells
in the context of type II GCTs, presence of part of the Y
chromosomeiscrucial,referredtoasgonadoblastomaonthe
Y chromosome (GBY) region by Page in 1987 [2]. TSPY is
currently considered to be the most likely candidate gene for
thisgenomicregion[10,11],andofdiagnosticvalue,because
both CIS and GB show coexpression of OCT3/4, SCF, and
TSPY.
In spite of the overall low incidence in the general
population, type II testicular GCTs are the most common
malignancy in Caucasian males aged between 15 and 45
years, the incidence of which is still rising [12]. It has been
suggested that the so-called testicular dysgenesis syndrome
(TDS) is the underlying reason [13], estimated to aﬀect
1 in 500 live births. However, existence of TDS is also
questioned [14]. TDS links various clinical observations like
cryptorchidism, subfertility/infertility, and hypospadias with
exposure to certain environmental factors, with either a
xenoestrogen or antiandrogen function. However, genetic
factors, especially a limited number of single nucleotide
polymorphisms (SNPs) are also recognized to play a role
in development of this type of cancer [15, 16]. Most likely,
the pathogenesis is a close and subtle interplay between
both genetic and environmental factors, referred by us to as
“Genvironment.”
Here three unique unrelated male patients are presented
demonstrating the relevance of TDS and DSD recognition
for early diagnosis of malignant type II GCTs, possibly
preventing progression to metastasized disease.
2.MaterialsandMethods
2.1. Patients. Three unrelated male patients, all with hypo-
spadias and cryptorchidism in their clinical history, are
described. All patients underwent hypospadias corrections,
and two patients had orchidopexy early in life. Two of the
patients were only retrospectively recognized as having DSD
based on the presence in a single gonad of GB next to CIS as
precursor lesions. The third patient described, having been
recognizedearlyinlifeashavingDSD/TDS(i.e.,hypospadias
and cryptorchidism), shows that early identiﬁcation of the
condition can lead to early detection of the cancer precursor
lesion before progression to invasiveness occurs. Detailed
description is presented in Section 3.
2.2. Tissue Samples. Collected tissue samples were diagnosed
according to WHO standards [17] by an experienced pathol-
ogist in gonadal pathology, including GCTs (JWO). The
use of tissue samples for scientiﬁc reasons was approved by
an institutional review board (MEC 02.981 and CCR2041).
Samples were used according to the “Code for Proper
Secondary Use of Human Tissue in The Netherlands” as
developed by the Dutch Federation of Medical Scientiﬁc
Societies (FMWV, Version 2002, updated 2011). Fresh tissue
m a t e r i a lw a sﬁ x e di n1 0 %b u ﬀered formalin for 24hrs and
paraﬃn embedded according to standard protocols.
2.3. Immunohistochemical Staining. Immunohistochemistry
was performed on paraﬃn-embedded tissue sections of 3-
μm thickness. Hematoxylin (Klinipath, Duiven, The Nether-
lands) and eosin (Klinipath) counterstaining was performed
according to standard procedures. After deparaﬃnization
and 5min incubation in 3% H2O2 to inactivate endogenous
peroxidase activity, antigen retrieval was carried out by
heating under pressure of up to 1.2bar in an appropriate
buﬀer; 0.01M sodium citrate (pH 6) or 0.01M EGTA,
0.01M TRIS (pH 9). After blocking endogenous biotin using
the avidin/biotin blocking kit (SP-2001, Vector Laborato-
ries, Burlingame, CA, USA), the sections were incubated
for either 2hrs at room temperature (OCT3/4, SOX9)
or overnight at 4◦C (TSPY, FOXL2, SCF). Appropriate
biotinylated secondary antibodies were used for detection
and were visualized using the avidin-biotin detection and
substrate kits (Vector Laboratories). The antibodies used
directed against OCT3/4, TSPY, SCF, SOX9, and FOXL2 have
been described before [7, 18–20].
2.4. Fluorescent In Situ Hybridization. Slides of 5μm thick-
ness were deparaﬃnized and heated under pressure of up to
1.2bar in appropriate buﬀer; 0.01M sodium citrate (pH 6).
Slides were digested using 0.01% pepsin (Sigma Aldrich, St.
Louis, MO, USA) in 0.02MHCl at 37◦C, with an optimal
digestion time of 2.5min. Slides were rinsed and dehydrated,
and the probes dissolved in hybridization mixture were
applied. Probes for centromere X (BamHI) and centromere
Y (DYZ3) were used, labeled with digoxigenin-11-dUTP and
biotin-16-dUTP (Roche Diagnostics, Mannheim, Germany)
using a nick-translation kit (Gibco BRL, Paisley, UK). After
denaturizing (80◦C for 10min), hybridization overnight
(37◦C),andwashingsteps,probeswerevisualizedusingCy3-
conjugated avidin (1:100, Jackson ImmunoResearch, West
Grove, PA, USA) and Sheep-anti-dig FITC (1:50, Roche
Diagnostics) and analyzed using a ﬂuorescent microscope
(Leica Microsystems, Rijswijk, The Netherlands).
2.5. Copy Number Analysis. Genomic DNA was isolated
from peripheral blood (patient 1 and 3) and frozen gonadal
tissue without presence of malignant cells (patient 2) usingInternational Journal of Endocrinology 3
standard procedures. For each sample, 200ng of DNA
was labelled and hybridized onto the Human OmniExpress
microarray (Illumina, San Diego, CA, USA) at the Australian
Genome Research Facility (Melbourne, Australia) follow-
ing manufacturer’s instructions. Data was analyzed with
Genome Studio (Illumina) and cnvPartition, using default
settings.
3. Results
3.1. Clinical History, Hormonal and Genetic Data, and
Immunohistochemical Analyses
Patient 1. Review of the existing clinical data was prompted
by the histological evaluation of the right testis at the age of
26 years (showing dysgenetic characteristics, see below). It
was found that the patient had multiple surgical corrections
of proximal hypospadias between his second and tenth year
of age, because of the severity of this anomaly. Orchidopexy
of the left testis by an inguinal approach was performed at
three years of age, while no right gonad was found during
inguinalexplorationontherightsideatthattime.At26years
ofage,thepatientunderwentsurgeryforaleft-sidedinguinal
hernia. During the procedure, the right testis (inguinal
position) was identiﬁed at the left hand side (i.e., crossed
testicular ectopia) and removed because of a macroscopically
abnormal/tumor-like appearance.
Histological examination of this gonad showed dysge-
netic characteristics, containing CIS, GB, DG, and SE (rep-
resentative hematoxylin and eosin (H&E) staining shown
in Figure 1(a)). The CIS- and GB-germ cells showed a
positive staining for OCT3/4 (Figure 1(b), brown), TSPY
(Figure 1(c), red), and SCF (Figure 1(d), brown). The sup-
portivecellsincontextofCISstainedpredominantly positive
for SOX9 (Figure 1(e), brown), while those in the context of
GB stained predominantly for FOXL2 (Figure 1(f), brown).
Coexpression is, however, observed, suggesting an issue of
balance. In line with current treatment options, the patient
received prophylactic radiotherapy according to standard
guidelines. During close followup (3 years), the patient
showed no relapse of the disease.
Genetic analysis by karyotyping of peripheral blood
lymphocytes, and FISH using X and Y centromeric probes
ongonadaltissue(representativeFISHshowninFigure 1(g))
indicated a normal male 46,XY constitution. Hormonal data
analysis at the age of 24 years indicated a suboptimal tes-
ticular function (hypergonadotropic hypogonadism), FSH
12 and 17.5U/L (normal 2.0–7.0U/L), LH 5.6 and 8.4U/L
(normal 1.5–8.0U/L), testosterone 13.2 and 16.2 (normal
10–30nmol/L), Inhibin B 119 and 74ng/L (normal 150–
400ng/L). Tumor markers measured after the removal of the
aﬀected gonad with the cancer showed a slightly elevated
level of AFP 15–19μg/L (normal < 10–15μg/L), normal
levels of β-HCG < 0.5IU/L (normal < 0.5IU/L), and LDH
152–314U/L (normal < 450U/L).
Taken together, the histological observations, clinical his-
tory, karyotyping, and hormonal data support the diagnosis
of the patient as a 46,XY DSD, type A: disorder of testicular
development, 1: partial gonadal dysgenesis [1]. A summary
of the various actions and observations is schematically
shown in Figure 1(h).
Patient 2. Review of the (limited) clinical history was pro-
vokedbythehistologicalevaluationofthelefttestisattheage
of 21 years, showing dysgenetic characteristics (see below).
It revealed presence of bilateral intra-abdominal testes, while
themalepatientalsoshowedhypospadias,aswellaspresence
of a uterus. At 20 years of age, the patient was diagnosed
with a right intra-abdominal testicular SE (of which no
material or further information could be retrieved). During
surgical removal of the aﬀected gonad, the left sided intra-
abdominal testis was positioned at an inguinal site. This
remaining testis was biopsied six months later because of
unexplained enlargement and was subsequently removed
b e c a u s eo fp r e s e n c eo fC I Sa n dG B( s e eb e l o w ) .
Histological evaluation of the left biopsy showed the
presence of GB and CIS, which was followed by orchidec-
tomy. Further histological examination indicated the pres-
ence of dysgenetic characteristics, CIS and GB (represen-
tative H&E shown in Figure 2(a)), supported by staining
for OCT3/4 (Figure 2(b), brown), TSPY (Figure 2(c), red),
and SCF (Figure 2(d), brown), next to SE and DG. The
supportive cells in GB stained again positive for FOXL2
(Figure 2(e), brown) and for SOX9 in CIS (Figure 2(f),
brown). Because of proven metastasized disease, the patient
received chemotherapy following standard procedures. No
follow-up information is available.
Genetic analysis by karyotyping of peripheral blood
lymphocytes and FISH using X and Y centromeric probes
on gonadal tissue indicated a normal male 46,XY karyotype
(data not shown). No hormonal or tumor marker data was
available.
In summary, histological evaluation, review of clinical
history, and karyotyping indicate that the patient must be
diagnosed as a 46,XY DSD, type A: disorder of testicular
development, 1: partial gonadal dysgenesis [1]. A summary
of the various actions and observations is schematically
shown in Figure 2(g).
Patient 3. The male patient showed multiple congenital
anomalies at birth, amongst other penoscrotal hypospadias
and bilaterally cryptorchid testes. He underwent multiple
hypospadias corrections at one and two years of age.
Orchidopexy of the right testis to a high scrotal position
was performed at two years of age, and a herniotomy and
orchidopexy, to a high scrotal position, of the left testis
was carried out at 3 years of age. Overall appearance of
the left testis together with total dissociation of epididymis
and testis prompted a biopsy to be taken at that time
(representative H&E shown in Figure 3(a)). It was diagnosed
as prepubertal testicular parenchyma with seminiferous
tubules containing Sertoli cells and germ cells, without
indication for malignancy. The patient was lost to followup
until 12 years of age at which time he was examined because
of incontinence problems and came under attention of the
initial clinician treating the hypospadias by coincidence.
Physical examination showed a pubertal boy (Tanner stage
P4G3) with a scrotal localization of the right testis, while4 International Journal of Endocrinology
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Figure 1: Immunohistochemical staining and ﬂuorescent in situ hybridization (FISH) of the gonadoblastoma and carcinoma in situ lesions
of patient 1. (a) Representative hematoxylin and eosin staining. The germ cells present in the GB and CIS stain positive for (b) OCT3/4
(brown),(c)TSPY(red),and(d)SCF(brown).(e)ThesupportivecellsintheCISlesionareSOX9positive(brownstaining)andarenegative
for FOXL2. (f) In the GB, the supportive cells stain positive for FOXL2 (brown staining) and are negative for SOX9. (a–f) In every image
the GB lesion is shown on the left side (embryonic germ cells intermixed with granulose-like supportive cells), CIS containing seminiferous
tubules on the right side (CIS cells associated with Sertoli cells on the basal lamina). Magniﬁcation 200x and 400x for all. Slides (b)–(f)
are counterstained with hematoxylin. (g) Representative FISH with Y-centromere-speciﬁc probe (shown in red) and X-centomere-speciﬁc
probe (shown in green). Magniﬁcation 630x. (h) Schematic representation of the diﬀerent moments in time of clinical intervention, blue
arrow, identiﬁcation of a malignant type II germ cell tumor, together with GB and CIS as precursor lesions at the age of 26 years. Review of
the clinical history showed hypospadias and cryptorchid testes, signs of TDS/DSD which were not recognized at an early age. Grey-dashed
arrows; early recognition of TDS/DSD could have allowed early detection and treatment of the malignancy, thereby, preventing the need for
additional systemic treatment.International Journal of Endocrinology 5
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Figure 2: Immunohistochemical staining of the gonadoblastoma and carcinoma in situ lesions of patient 2. (a) Representative hematoxylin
and eosin staining. Positive staining for (b) OCT3/4 (brown), (c) TSPY (red), and (d) SCF (brown) of the germ cells present in the GB and
CIS. (e) In the GB the supportive cells stain positive for FOXL2 (brown). (f) The supportive cells in the CIS lesion are SOX9 positive (brown
staining) and are negative for FOXL2. (a–d), (f) Again, both GB (embryonic germ cells intermixed with granulose-like supportive cells) and
CIS (associated with Sertoli cells on the basal membrane of the tubules) are shown. Magniﬁcation 200x and 400x for all. Slides (b)–(f) are
counterstained with hematoxylin. (g) Timeline showing the clinical history, histology, and actions taken.
the left testis was not palpable. Further examination using
ultrasound showed an inguinal position of the left testis
(ascending testis) and bilateral testicular microcalciﬁcations
(microlithiasis). Because of the inability to position the left
testis in the scrotum, and the knowledge about the increased
risk for development of a malignant GCT based on the
clinical characteristics, the left testicle was removed, and the
right testis was biopsied.
Histological examination of the left testis (representative
H&E staining shown in Figure 3(d)) showed seminiferous6 International Journal of Endocrinology
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Figure 3: Immunohistochemical staining of the carcinoma in situ lesion of patient 3 at three and twelve years of age. (a) Representative
hematoxylin and eosin staining. Positive staining for (b) OCT3/4 (brown), (c) TSPY (red) of the germ cells present in the CIS. (a–c) Biopsy
tissue at 3 years of age. (d) Representative hematoxylin and eosin staining. Positive staining for (e) OCT3/4 (brown), (f) TSPY (red), and
(g) SCF (brown) of the CIS cells. (d–g) Gonadal tissue at 12 years of age. (e–g) Region indicated with a square in (d) is shown. Note
the expression of OCT3/4, TSPY, and SCF in the CIS cell indicated by the arrow. Magniﬁcation 200x and 400x for all. Slides (b)–(g) are
counterstained with hematoxylin. (h) Timeline showing the clinical history, histology, and actions taken.International Journal of Endocrinology 7
tubules containing CIS, supported by staining for OCT3/4
(Figure 3(e), brown), TSPY (Figure 3(f), red), and SCF
(Figure 3(g), brown). Costaining of these markers in single
CIS cells was identiﬁed (indicated by the arrow). The
presence of CIS initiated reexamination of the biopsy taken
attheageofthreeyears.Becauseoflimitedmaterialavailable,
only staining for OCT3/4 (Figure 3(b), brown) and TSPY
(Figure 3(c), red) could be done, showing the presence
of premalignant germ cells, referred to as pre-CIS. This
conclusion was not made at the time of original sampling
because of lack of appropriate markers. The biopsy taken
from the right testis showed normal testicular parenchyma
without malignancy (negative OCT3/4 staining, data not
shown).
Genetic analysis by karyotyping of peripheral blood
lymphocytes and FISH using X and Y centromeric probes
on gonadal tissue indicated a normal male 46,XY karyotype
(data not shown). Hormonal data at the age of 12 years
were as follows: FSH 1.8 and 3.1U/L (normal < 6.0U/L),
LH 0.4 and 1.0U/L (normal < 2.5U/L), testosterone 1.6 and
6.7nmol/L (normal 3.0–6.5nmol/L), and AMH 18.8μg/L
(normal 30–200μg/L). The tumor markers tested were
within the normal range: AFP < 1μg/L (normal < 10μg/L)
and β-HCG 0.1IU/L (normal < 0.5IU/L).
Taken together, histological evaluation, review of clinical
history, and karyotyping indicate that the patient must be
diagnosed as 46,XY DSD, type A: disorder of testicular devel-
opment, 1: partial gonadal dysgenesis [1]. A summary of
the various actions and observations in time is schematically
shown in Figure 3(h).
3.2. Copy Number Analysis of Known DSD Genes. Ap e r i p h -
eral blood DNA sample from patient 1 and 3 and a DNA
sample isolated from frozen gonadal tissue from patient 2
(as no peripheral blood was available) were checked for
copy number changes by genome-wide SNP analysis using
Illumina OmniExpress Beadchips. This supported the 46,XY
karyotype and showed no aberrations aﬀecting known DSD
genes (data not shown).
4. Discussion
Here, two unrelated male patients are presented, both
diagnosed with an invasive malignant type II GCT. One
was prophylactically treated with irradiation for a stage I
seminoma, and the other received chemotherapy for proven
metastasized disease. These treatment protocols have been
found to increase the risk for long-term sequelae [21].
Presence of GB, known to be associated with DSD [8],
besidesCIS,asprecursorinthesepatients,triggeredreviewof
their clinical history. Both cases showed severe hypospadias
and cryptorchidism. These are identiﬁers of DSD, as well
as TDS, both conditions known for their increased risk of
malignant type II GCTs [3, 13]. In addition, patient 1 had
crossed testicular ectopia, a very rare anomaly, reported to be
associated with TDS and DSD [22]. No genetic conﬁrmation
of an underlying DSD was found in any of the patients,
even using high-resolution genome wide analysis. In spite
of this lack of identiﬁcation of the molecular basis of
the underlying disorder, the observations have signiﬁcant
implications regarding development of strategies for early
diagnosis of type II GCTs, as well as understanding the
biology of the disease.
DSD patients can be diagnosed early in life based on
various characteristics, including sexual ambiguity, family
history, discordant karyotype and genital appearance, and
aberrant male and female genitalia. In children and young
adults, however, DSD can present as an inguinal hernia in
a girl, incomplete or delayed puberty, virilization in a girl,
primary amenorrhea, breast development in a boy, and a
previously unrecognized genital ambiguity [1].
When sex determination is disrupted in an early stage
of Sertoli cell diﬀerentiation, a high risk for GB is found
[9]. The GB lesion is composed of immature germ cells
intermixed with supportive cells classiﬁed as granulosa [23].
The GB lesions found in the two presented patients showed
these characteristics as well, based on immunohistochemical
ﬁnding using OCT3/4, TSPY, SCF, SOX9, and FOXL2. Next
to the GB component, CIS was also present in both. This
in fact triggered the search for additional clinical arguments
in line with the diagnose of these patients as DSD. The
ﬁndings presented indicate that, by proper application of the
current knowledge of risk factors for type II GCTs, these
patients could have been diagnosed earlier, thereby, possibly
preventing the use of irradiation and chemotherapy. That
this is in fact a feasible option is demonstrated by the third
patient presented. It demonstrates the power of applying the
current markers for diagnosis of the premalignant lesions
of type II GCTs. In fact, reevaluation of the biopsy of this
patient, taken at three years of age, showed coexpression of
OCT3/4 and TSPY in germ cells located on the basal lamina.
T h e s ec e l l sa r er e f e r r e dt oa sp r e - C I S ,f r o mw h i c hC I Sw i l l
develop. Proper identiﬁcation of the risk factors for type II
GCTs, in particular related to DSD and TDS, will increase
thepossibilitytoidentifypatientsatriskformalignancyatan
early age, allowing application of limited-harmful treatment
protocols.
OCT3/4 expression is most likely related to the survival
of the germ cells [24], while the role of TSPY is less clear.
It has been suggested to be related to cell-cycle regulation
[25–27]. In addition, SCF is informative to diagnose CIS and
GB, especially to distinguish CIS from germ cells delayed
in their maturation [28]. Of interest in this context is the
linkage of speciﬁc single nucleotide polymorphisms with
development of type II GCTs in the general Caucasian
population,includinginvolvementofSCF[15,16].However,
the impact of these risk alleles in the DSD populations
remains to be investigated.
The left testis of patient 1 and the right testis of patient 3
are still in situ at a scrotal localization. For the ﬁrst patient
available hormonal data indicated suboptimal testicular
function (high FSH, low inhibin, testosterone low normal
range). In spite of treatment by prophylactic irradiation,
and absence of metastasis (based on routine examinations),
the patient is under close surveillance because of a minor
elevated AFP level. No hormonal indications for testicular
dysfunction could be observed in patient 3, while no data
were available for patient 2.8 International Journal of Endocrinology
Recently two families have been independently reported
showing an overlap between DSD and TDS. One family
showed two sisters with XY sex reversal, gonadal dysgenesis,
and GB, and the other family included one daughter with
a mosaic karyotype and GB. All patients showed a SRY
mutation, inherited from the father, being mosaic. The
fathers of both families presented with TDS, one with
oligoasthenozoospermia, and a testicular SE, the other with
hypospadias, cryptorchidism, oligoasthenozoospermia, and
at e s t i c u l a rS Ea sw e l l[ 29, 30]. In other words, TDS and
DSD form a continuum, which is informative to identify
individuals at risk for type II GCTs.
As indicated, the two patients demonstrated here with
a type II GCT, and proven metastasized cancer in one, at
time of diagnosis, also show the value of identiﬁcation of
parameters known to be related to TDS and DSD, including
cryptorchidism, hypospadias, and the presence of GB (in
the latter). Based on these characteristics, these two patients
would have been diagnosed as 46,XY DSD, disorder of
testicular development, 1: partial gonadal dysgenesis [1],
beingatincreasedriskfordevelopmentofamalignanttypeII
GCT. Feasibility of early diagnosis, leading to the prevention
of development of an invasive, and possibly even a metastatic
cancer, is clearly demonstrated by the third patient.
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